Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, Non-Hodgkin | 45 | 2022 | 261 | 9.710 |
Why?
|
Multiple Myeloma | 19 | 2023 | 307 | 4.690 |
Why?
|
Case-Control Studies | 51 | 2022 | 1801 | 1.980 |
Why?
|
5-Methylcytosine | 7 | 2023 | 110 | 1.820 |
Why?
|
Cell-Free Nucleic Acids | 4 | 2022 | 69 | 1.780 |
Why?
|
Diet | 9 | 2013 | 442 | 1.590 |
Why?
|
Lymphoma, Follicular | 7 | 2022 | 70 | 1.530 |
Why?
|
Occupational Exposure | 10 | 2018 | 80 | 1.480 |
Why?
|
Antirheumatic Agents | 3 | 2020 | 51 | 1.440 |
Why?
|
Aged | 84 | 2022 | 18353 | 1.440 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 6 | 2019 | 151 | 1.330 |
Why?
|
Risk Factors | 55 | 2022 | 5397 | 1.330 |
Why?
|
Vegetables | 6 | 2013 | 45 | 1.290 |
Why?
|
Translocation, Genetic | 5 | 2009 | 265 | 1.210 |
Why?
|
Middle Aged | 82 | 2021 | 24957 | 1.180 |
Why?
|
Feeding Behavior | 6 | 2013 | 324 | 1.080 |
Why?
|
Female | 106 | 2022 | 44405 | 1.080 |
Why?
|
Agricultural Workers' Diseases | 5 | 2009 | 18 | 1.060 |
Why?
|
Humans | 143 | 2023 | 86281 | 1.050 |
Why?
|
Male | 99 | 2022 | 40860 | 1.040 |
Why?
|
Aged, 80 and over | 40 | 2021 | 6481 | 1.020 |
Why?
|
Smoking | 9 | 2014 | 605 | 1.020 |
Why?
|
Fruit | 4 | 2013 | 75 | 1.000 |
Why?
|
Life Style | 8 | 2015 | 188 | 0.950 |
Why?
|
Chromosomes, Human, Pair 18 | 3 | 2008 | 42 | 0.930 |
Why?
|
Chromosomes, Human, Pair 14 | 3 | 2008 | 49 | 0.920 |
Why?
|
Adult | 75 | 2021 | 25577 | 0.900 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 8 | 0.880 |
Why?
|
Pesticides | 3 | 2009 | 28 | 0.860 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 3 | 2016 | 22 | 0.810 |
Why?
|
Odds Ratio | 17 | 2021 | 677 | 0.790 |
Why?
|
Hematologic Neoplasms | 5 | 2016 | 329 | 0.790 |
Why?
|
Meat | 4 | 2012 | 26 | 0.770 |
Why?
|
Health Status Disparities | 2 | 2021 | 170 | 0.770 |
Why?
|
Nebraska | 10 | 2012 | 14 | 0.740 |
Why?
|
Neoplasms, Second Primary | 2 | 2021 | 252 | 0.730 |
Why?
|
Body Mass Index | 8 | 2017 | 770 | 0.730 |
Why?
|
Arthritis, Rheumatoid | 3 | 2018 | 163 | 0.720 |
Why?
|
Parkinson Disease | 1 | 2021 | 132 | 0.720 |
Why?
|
Healthcare Disparities | 2 | 2021 | 369 | 0.700 |
Why?
|
Hematologic Agents | 1 | 2018 | 4 | 0.690 |
Why?
|
United States | 24 | 2023 | 6637 | 0.690 |
Why?
|
Filgrastim | 1 | 2018 | 56 | 0.680 |
Why?
|
SEER Program | 13 | 2022 | 181 | 0.660 |
Why?
|
Neutropenia | 1 | 2018 | 215 | 0.640 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2020 | 683 | 0.640 |
Why?
|
Biological Products | 1 | 2020 | 143 | 0.620 |
Why?
|
Genetic Predisposition to Disease | 9 | 2022 | 2267 | 0.610 |
Why?
|
Chlamydophila pneumoniae | 6 | 2003 | 12 | 0.600 |
Why?
|
Inflammasomes | 1 | 2017 | 23 | 0.600 |
Why?
|
Bronchial Neoplasms | 1 | 2016 | 9 | 0.570 |
Why?
|
Polyethylene Glycols | 1 | 2018 | 363 | 0.570 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2013 | 35 | 0.560 |
Why?
|
Autophagy | 1 | 2017 | 148 | 0.530 |
Why?
|
Myelodysplastic Syndromes | 1 | 2018 | 345 | 0.530 |
Why?
|
Proportional Hazards Models | 6 | 2020 | 857 | 0.500 |
Why?
|
Heart Failure | 3 | 2022 | 1196 | 0.490 |
Why?
|
Alcohol Drinking | 6 | 2013 | 264 | 0.490 |
Why?
|
Lymphoma | 2 | 2013 | 262 | 0.480 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2014 | 111 | 0.480 |
Why?
|
Drug Carriers | 1 | 2014 | 81 | 0.470 |
Why?
|
Obesity | 5 | 2008 | 962 | 0.470 |
Why?
|
Chromosome Aberrations | 2 | 2020 | 386 | 0.470 |
Why?
|
Incidence | 11 | 2023 | 1568 | 0.470 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 80 | 0.470 |
Why?
|
Doxorubicin | 1 | 2014 | 289 | 0.470 |
Why?
|
Diet, Western | 1 | 2013 | 37 | 0.450 |
Why?
|
Occupational Diseases | 4 | 2018 | 55 | 0.450 |
Why?
|
Phytanic Acid | 1 | 2012 | 3 | 0.450 |
Why?
|
Kidney Neoplasms | 4 | 2011 | 620 | 0.450 |
Why?
|
Nitrites | 1 | 2012 | 30 | 0.440 |
Why?
|
Sex Factors | 12 | 2020 | 1053 | 0.440 |
Why?
|
Nitrates | 1 | 2012 | 35 | 0.440 |
Why?
|
Tertiary Care Centers | 1 | 2013 | 93 | 0.440 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2018 | 755 | 0.440 |
Why?
|
Prospective Studies | 12 | 2020 | 4194 | 0.410 |
Why?
|
Young Adult | 21 | 2021 | 5961 | 0.410 |
Why?
|
Retrospective Studies | 14 | 2022 | 8431 | 0.410 |
Why?
|
Diphosphonates | 2 | 2021 | 36 | 0.390 |
Why?
|
Sunlight | 2 | 2008 | 26 | 0.390 |
Why?
|
Follow-Up Studies | 12 | 2018 | 3616 | 0.390 |
Why?
|
Prognosis | 5 | 2020 | 3669 | 0.390 |
Why?
|
Surveys and Questionnaires | 14 | 2020 | 2495 | 0.380 |
Why?
|
Frailty | 2 | 2022 | 56 | 0.380 |
Why?
|
Logistic Models | 10 | 2019 | 1184 | 0.380 |
Why?
|
Neuroblastoma | 1 | 2014 | 374 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 859 | 0.370 |
Why?
|
Genome-Wide Association Study | 7 | 2022 | 1611 | 0.370 |
Why?
|
Medicare | 7 | 2022 | 404 | 0.360 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2022 | 2350 | 0.360 |
Why?
|
Carcinoma, Renal Cell | 3 | 2011 | 425 | 0.350 |
Why?
|
Biomedical Research | 2 | 2023 | 375 | 0.340 |
Why?
|
Chlamydia Infections | 3 | 2003 | 25 | 0.340 |
Why?
|
Hodgkin Disease | 3 | 2016 | 177 | 0.330 |
Why?
|
Lymphoma, B-Cell | 2 | 2022 | 103 | 0.330 |
Why?
|
Carotid Artery Diseases | 2 | 2013 | 97 | 0.330 |
Why?
|
Databases, Factual | 4 | 2023 | 808 | 0.320 |
Why?
|
Adolescent | 23 | 2022 | 8968 | 0.320 |
Why?
|
Breast Neoplasms | 7 | 2022 | 2881 | 0.320 |
Why?
|
Hair Dyes | 1 | 2007 | 2 | 0.300 |
Why?
|
Age Factors | 11 | 2019 | 1842 | 0.300 |
Why?
|
Vitamins | 1 | 2007 | 81 | 0.300 |
Why?
|
Comorbidity | 4 | 2021 | 943 | 0.290 |
Why?
|
Vaccination | 1 | 2008 | 253 | 0.290 |
Why?
|
Immunity, Humoral | 2 | 2021 | 67 | 0.290 |
Why?
|
Colorectal Neoplasms | 3 | 2004 | 924 | 0.270 |
Why?
|
Dietary Fats | 4 | 2012 | 134 | 0.270 |
Why?
|
Diet Surveys | 3 | 2013 | 20 | 0.270 |
Why?
|
Motor Activity | 2 | 2006 | 327 | 0.270 |
Why?
|
Cohort Studies | 9 | 2020 | 2759 | 0.270 |
Why?
|
Endarterectomy, Carotid | 2 | 2003 | 73 | 0.260 |
Why?
|
Acetyltransferases | 1 | 2005 | 29 | 0.260 |
Why?
|
Vitamin D | 1 | 2007 | 261 | 0.260 |
Why?
|
Glutathione Transferase | 1 | 2005 | 111 | 0.260 |
Why?
|
Confidence Intervals | 6 | 2008 | 228 | 0.250 |
Why?
|
Risk | 5 | 2012 | 673 | 0.240 |
Why?
|
Anthropometry | 3 | 2017 | 74 | 0.230 |
Why?
|
Europe | 5 | 2014 | 308 | 0.230 |
Why?
|
South Carolina | 1 | 2023 | 3 | 0.230 |
Why?
|
Spatial Analysis | 1 | 2023 | 7 | 0.230 |
Why?
|
New York | 1 | 2023 | 69 | 0.230 |
Why?
|
Arylamine N-Acetyltransferase | 2 | 2012 | 11 | 0.220 |
Why?
|
Iowa | 7 | 2011 | 35 | 0.220 |
Why?
|
Treatment Outcome | 6 | 2021 | 7949 | 0.220 |
Why?
|
Mucopolysaccharidosis III | 1 | 2022 | 1 | 0.220 |
Why?
|
Dietary Fiber | 3 | 2011 | 43 | 0.220 |
Why?
|
Prostate-Specific Antigen | 1 | 2005 | 346 | 0.220 |
Why?
|
Asbestos | 1 | 2002 | 22 | 0.220 |
Why?
|
Diet Records | 3 | 2013 | 19 | 0.220 |
Why?
|
Australia | 4 | 2014 | 99 | 0.220 |
Why?
|
Rituximab | 3 | 2018 | 116 | 0.220 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 78 | 0.210 |
Why?
|
North America | 4 | 2014 | 179 | 0.210 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 3 | 0.210 |
Why?
|
Health Status | 2 | 2020 | 360 | 0.210 |
Why?
|
Isoenzymes | 2 | 2012 | 271 | 0.210 |
Why?
|
Dietary Proteins | 2 | 1999 | 30 | 0.210 |
Why?
|
Adenoma | 1 | 2004 | 234 | 0.210 |
Why?
|
Insulin-Like Growth Factor I | 3 | 2009 | 114 | 0.200 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 50 | 0.200 |
Why?
|
Bone Diseases | 1 | 2021 | 54 | 0.200 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 114 | 0.200 |
Why?
|
Solvents | 2 | 2018 | 95 | 0.200 |
Why?
|
Aneurysm | 1 | 2001 | 58 | 0.200 |
Why?
|
Depression | 2 | 2019 | 472 | 0.200 |
Why?
|
Polymorphism, Genetic | 1 | 2005 | 819 | 0.200 |
Why?
|
Bone Density Conservation Agents | 1 | 2021 | 45 | 0.200 |
Why?
|
Renal Artery | 1 | 2001 | 64 | 0.190 |
Why?
|
Biomarkers, Tumor | 3 | 2019 | 1461 | 0.190 |
Why?
|
Taiwan | 5 | 2022 | 23 | 0.190 |
Why?
|
Self Report | 2 | 2020 | 287 | 0.190 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2020 | 348 | 0.190 |
Why?
|
Cytogenetic Analysis | 1 | 2020 | 71 | 0.190 |
Why?
|
Quality of Life | 4 | 2022 | 1575 | 0.190 |
Why?
|
Genetic Loci | 3 | 2020 | 250 | 0.190 |
Why?
|
Mass Screening | 1 | 2005 | 615 | 0.190 |
Why?
|
Viral Proteins | 1 | 2021 | 300 | 0.180 |
Why?
|
Arthritis | 1 | 2020 | 46 | 0.180 |
Why?
|
Cardiomyopathies | 1 | 2022 | 240 | 0.180 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 230 | 0.180 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 328 | 0.170 |
Why?
|
Exercise | 4 | 2022 | 315 | 0.170 |
Why?
|
Stem Cell Transplantation | 1 | 2020 | 183 | 0.170 |
Why?
|
Colonic Neoplasms | 2 | 2003 | 554 | 0.170 |
Why?
|
Occupations | 2 | 2016 | 26 | 0.170 |
Why?
|
Carotid Arteries | 2 | 2013 | 127 | 0.170 |
Why?
|
Imaging, Three-Dimensional | 2 | 2013 | 579 | 0.170 |
Why?
|
Hydrocarbons, Aromatic | 1 | 2018 | 3 | 0.170 |
Why?
|
Interleukin-6 | 1 | 2020 | 255 | 0.170 |
Why?
|
Mental Health | 1 | 2019 | 160 | 0.170 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 265 | 0.170 |
Why?
|
Hip Fractures | 1 | 1999 | 45 | 0.160 |
Why?
|
Thyroid Neoplasms | 2 | 2013 | 406 | 0.160 |
Why?
|
Postmenopause | 1 | 1999 | 98 | 0.160 |
Why?
|
Sex Characteristics | 1 | 2020 | 319 | 0.160 |
Why?
|
Blood Transfusion | 1 | 2019 | 157 | 0.160 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2018 | 165 | 0.160 |
Why?
|
Information Storage and Retrieval | 1 | 2018 | 120 | 0.160 |
Why?
|
Sjogren's Syndrome | 2 | 2016 | 30 | 0.160 |
Why?
|
Infliximab | 2 | 2016 | 151 | 0.160 |
Why?
|
Cytomegalovirus | 1 | 1997 | 76 | 0.150 |
Why?
|
Neoplasm Staging | 4 | 2019 | 1932 | 0.150 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 3 | 2009 | 21 | 0.150 |
Why?
|
Multiple Organ Failure | 1 | 2017 | 52 | 0.150 |
Why?
|
Up-Regulation | 2 | 2012 | 710 | 0.150 |
Why?
|
Energy Intake | 2 | 2008 | 97 | 0.150 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2001 | 376 | 0.150 |
Why?
|
Adenocarcinoma | 3 | 2001 | 1160 | 0.150 |
Why?
|
Metabolic Networks and Pathways | 1 | 2017 | 78 | 0.150 |
Why?
|
Proteolysis | 1 | 2017 | 100 | 0.150 |
Why?
|
Epidemiologic Studies | 3 | 2016 | 17 | 0.150 |
Why?
|
Dementia | 1 | 2018 | 187 | 0.140 |
Why?
|
Job Description | 1 | 2016 | 8 | 0.140 |
Why?
|
Carotid Stenosis | 1 | 1997 | 112 | 0.140 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2016 | 20 | 0.140 |
Why?
|
Cognitive Dysfunction | 1 | 2018 | 132 | 0.140 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 185 | 0.140 |
Why?
|
Antineoplastic Agents | 4 | 2019 | 2351 | 0.140 |
Why?
|
Cough | 1 | 2016 | 53 | 0.140 |
Why?
|
Cross-Sectional Studies | 6 | 2011 | 1610 | 0.140 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2016 | 131 | 0.140 |
Why?
|
Carcinoma | 3 | 2013 | 434 | 0.140 |
Why?
|
Dyspnea | 1 | 2016 | 72 | 0.140 |
Why?
|
Prostatic Neoplasms | 2 | 2005 | 1708 | 0.140 |
Why?
|
Silicone Gels | 2 | 2008 | 3 | 0.130 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 387 | 0.130 |
Why?
|
Testosterone | 2 | 2007 | 268 | 0.130 |
Why?
|
Survival Analysis | 3 | 2014 | 1536 | 0.130 |
Why?
|
Telomere | 1 | 2016 | 107 | 0.130 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 380 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2001 | 645 | 0.130 |
Why?
|
Breast Implants | 2 | 2008 | 23 | 0.130 |
Why?
|
Animals | 14 | 2019 | 26518 | 0.130 |
Why?
|
Herpesvirus 1, Human | 1 | 1997 | 244 | 0.130 |
Why?
|
Silk | 1 | 2014 | 1 | 0.130 |
Why?
|
Major Histocompatibility Complex | 1 | 2015 | 81 | 0.130 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 22 | 0.130 |
Why?
|
Chromosomes, Human | 1 | 2014 | 66 | 0.130 |
Why?
|
Pedigree | 3 | 2007 | 966 | 0.130 |
Why?
|
Kidney Transplantation | 1 | 2001 | 846 | 0.120 |
Why?
|
Genetic Association Studies | 1 | 2016 | 294 | 0.120 |
Why?
|
Delayed-Action Preparations | 1 | 2014 | 116 | 0.120 |
Why?
|
HLA Antigens | 2 | 2014 | 232 | 0.120 |
Why?
|
Sepsis | 1 | 2017 | 304 | 0.120 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 927 | 0.120 |
Why?
|
Agriculture | 2 | 2015 | 38 | 0.120 |
Why?
|
Nutritive Value | 1 | 2013 | 5 | 0.120 |
Why?
|
Diet, Vegetarian | 1 | 2013 | 8 | 0.120 |
Why?
|
Patient Outcome Assessment | 1 | 2014 | 83 | 0.120 |
Why?
|
Nutrition Assessment | 1 | 2013 | 21 | 0.120 |
Why?
|
Combined Modality Therapy | 2 | 2014 | 1680 | 0.110 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 136 | 0.110 |
Why?
|
Bacterial Infections | 1 | 2015 | 181 | 0.110 |
Why?
|
Practice Patterns, Physicians' | 2 | 2016 | 578 | 0.110 |
Why?
|
Tumor Burden | 1 | 2014 | 288 | 0.110 |
Why?
|
Factor Analysis, Statistical | 1 | 2013 | 111 | 0.110 |
Why?
|
Receptor, Endothelin A | 1 | 2012 | 22 | 0.110 |
Why?
|
Liver Neoplasms | 1 | 2019 | 731 | 0.110 |
Why?
|
Endothelins | 1 | 2012 | 35 | 0.110 |
Why?
|
Meat Products | 1 | 2012 | 7 | 0.110 |
Why?
|
Multivariate Analysis | 5 | 2012 | 997 | 0.110 |
Why?
|
Oleic Acid | 1 | 2012 | 14 | 0.110 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2012 | 33 | 0.110 |
Why?
|
Ovulation Inhibition | 1 | 2012 | 2 | 0.110 |
Why?
|
Femoral Artery | 1 | 2013 | 81 | 0.110 |
Why?
|
Mutagens | 1 | 2012 | 31 | 0.110 |
Why?
|
Reproductive History | 1 | 2012 | 8 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2014 | 458 | 0.110 |
Why?
|
Endothelin-1 | 1 | 2012 | 41 | 0.110 |
Why?
|
Bell Palsy | 1 | 2012 | 3 | 0.110 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2012 | 18 | 0.110 |
Why?
|
Graft Survival | 2 | 2010 | 883 | 0.110 |
Why?
|
Membrane Glycoproteins | 1 | 2015 | 428 | 0.110 |
Why?
|
Leukemia | 2 | 2006 | 318 | 0.110 |
Why?
|
Cytosine | 2 | 2023 | 127 | 0.110 |
Why?
|
Quinoxalines | 1 | 2012 | 50 | 0.110 |
Why?
|
Mice, Nude | 1 | 2014 | 790 | 0.110 |
Why?
|
Plaque, Atherosclerotic | 1 | 2013 | 54 | 0.110 |
Why?
|
Environmental Exposure | 2 | 2007 | 296 | 0.110 |
Why?
|
Dizziness | 1 | 2012 | 27 | 0.110 |
Why?
|
Cause of Death | 1 | 2013 | 277 | 0.110 |
Why?
|
Pyelonephritis | 1 | 2012 | 9 | 0.110 |
Why?
|
Software | 1 | 2016 | 650 | 0.100 |
Why?
|
Genotype | 4 | 2015 | 1850 | 0.100 |
Why?
|
Micronutrients | 1 | 2011 | 17 | 0.100 |
Why?
|
Gases | 1 | 2012 | 28 | 0.100 |
Why?
|
Vertigo | 1 | 2012 | 42 | 0.100 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 1047 | 0.100 |
Why?
|
Ultrasonography | 2 | 2013 | 695 | 0.100 |
Why?
|
Klebsiella Infections | 1 | 2012 | 25 | 0.100 |
Why?
|
Emphysema | 1 | 2012 | 22 | 0.100 |
Why?
|
Radiography, Abdominal | 1 | 2012 | 71 | 0.100 |
Why?
|
Ventricular Function, Right | 1 | 2012 | 142 | 0.100 |
Why?
|
Public Sector | 1 | 2011 | 12 | 0.100 |
Why?
|
Private Sector | 1 | 2011 | 19 | 0.100 |
Why?
|
C-Reactive Protein | 2 | 2010 | 190 | 0.100 |
Why?
|
Chlamydia trachomatis | 2 | 2001 | 14 | 0.100 |
Why?
|
Vascular Diseases | 1 | 2012 | 119 | 0.100 |
Why?
|
Steroids | 1 | 2012 | 172 | 0.100 |
Why?
|
Hepatitis B virus | 1 | 2010 | 42 | 0.100 |
Why?
|
Birth Order | 1 | 2010 | 8 | 0.100 |
Why?
|
Bioprosthesis | 1 | 2010 | 36 | 0.090 |
Why?
|
Hepatitis B | 1 | 2010 | 72 | 0.090 |
Why?
|
Cell Line, Tumor | 2 | 2014 | 2421 | 0.090 |
Why?
|
Lymphoproliferative Disorders | 1 | 2010 | 107 | 0.090 |
Why?
|
Graft Rejection | 2 | 2010 | 1064 | 0.090 |
Why?
|
World Health Organization | 1 | 2010 | 103 | 0.090 |
Why?
|
Spondylitis, Ankylosing | 1 | 2010 | 24 | 0.090 |
Why?
|
Hong Kong | 3 | 2021 | 45 | 0.090 |
Why?
|
Atherosclerosis | 1 | 2013 | 243 | 0.090 |
Why?
|
Blood Proteins | 1 | 2010 | 144 | 0.090 |
Why?
|
Patient Discharge | 1 | 2012 | 296 | 0.090 |
Why?
|
Anti-Bacterial Agents | 3 | 2012 | 739 | 0.090 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 8 | 0.090 |
Why?
|
Population Groups | 1 | 2008 | 41 | 0.080 |
Why?
|
China | 3 | 2007 | 228 | 0.080 |
Why?
|
Transplantation Tolerance | 1 | 2010 | 130 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 1 | 2011 | 237 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2434 | 0.080 |
Why?
|
Pulmonary Artery | 1 | 2010 | 305 | 0.080 |
Why?
|
Blood Vessel Prosthesis | 1 | 2010 | 228 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 2594 | 0.080 |
Why?
|
Emergency Service, Hospital | 1 | 2012 | 484 | 0.080 |
Why?
|
Acculturation | 1 | 2008 | 14 | 0.080 |
Why?
|
Autoimmune Diseases | 2 | 2008 | 241 | 0.080 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2010 | 208 | 0.080 |
Why?
|
Hypersensitivity | 1 | 2009 | 153 | 0.080 |
Why?
|
Interviews as Topic | 2 | 2007 | 319 | 0.080 |
Why?
|
Primary Health Care | 1 | 2011 | 339 | 0.080 |
Why?
|
Chemokines | 1 | 2007 | 72 | 0.080 |
Why?
|
Cytokines | 2 | 2010 | 775 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2008 | 109 | 0.080 |
Why?
|
Chromosomes, Human, 16-18 | 1 | 2007 | 26 | 0.080 |
Why?
|
Cocarcinogenesis | 1 | 2007 | 12 | 0.080 |
Why?
|
Chromosomes, Human, 13-15 | 1 | 2007 | 32 | 0.080 |
Why?
|
Emigrants and Immigrants | 1 | 2008 | 44 | 0.080 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2006 | 20 | 0.070 |
Why?
|
Receptors, Androgen | 1 | 2007 | 110 | 0.070 |
Why?
|
Child | 7 | 2013 | 6913 | 0.070 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 567 | 0.070 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 17 | 0.070 |
Why?
|
Q Fever | 1 | 2006 | 8 | 0.070 |
Why?
|
Sex Distribution | 1 | 2007 | 173 | 0.070 |
Why?
|
Endocarditis, Bacterial | 1 | 2006 | 33 | 0.070 |
Why?
|
Heparitin Sulfate | 2 | 2022 | 27 | 0.070 |
Why?
|
STAT3 Transcription Factor | 1 | 2006 | 78 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 916 | 0.070 |
Why?
|
Mesothelioma | 2 | 1990 | 309 | 0.070 |
Why?
|
Seasons | 1 | 2007 | 223 | 0.070 |
Why?
|
Health Behavior | 1 | 2007 | 183 | 0.070 |
Why?
|
Immunotherapy | 3 | 2019 | 627 | 0.070 |
Why?
|
Population Surveillance | 1 | 2007 | 219 | 0.070 |
Why?
|
Arteriosclerosis | 2 | 2002 | 113 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.070 |
Why?
|
Health Fairs | 1 | 2005 | 2 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 2005 | 59 | 0.070 |
Why?
|
Mice | 5 | 2014 | 11313 | 0.060 |
Why?
|
Internal-External Control | 1 | 2005 | 44 | 0.060 |
Why?
|
Insulin Resistance | 1 | 2007 | 377 | 0.060 |
Why?
|
Employment | 1 | 2005 | 52 | 0.060 |
Why?
|
Income | 1 | 2005 | 75 | 0.060 |
Why?
|
Hyaluronic Acid | 1 | 1984 | 49 | 0.060 |
Why?
|
Kansas | 1 | 2004 | 6 | 0.060 |
Why?
|
Child, Preschool | 4 | 2013 | 3608 | 0.060 |
Why?
|
Minnesota | 1 | 2004 | 46 | 0.060 |
Why?
|
Mammography | 1 | 2007 | 460 | 0.060 |
Why?
|
Sigmoidoscopy | 1 | 2004 | 36 | 0.060 |
Why?
|
Hypertension | 4 | 2012 | 1139 | 0.060 |
Why?
|
Recurrence | 2 | 2021 | 1137 | 0.060 |
Why?
|
Neoplasms | 1 | 2019 | 2889 | 0.060 |
Why?
|
Air Pollutants, Occupational | 1 | 2003 | 6 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2016 | 2699 | 0.060 |
Why?
|
Eggs | 1 | 2003 | 12 | 0.060 |
Why?
|
Stroke | 1 | 2012 | 959 | 0.060 |
Why?
|
Hypercalcemia | 2 | 2021 | 59 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 3347 | 0.060 |
Why?
|
Clarithromycin | 1 | 2002 | 7 | 0.060 |
Why?
|
Construction Materials | 1 | 2002 | 1 | 0.060 |
Why?
|
Metallurgy | 1 | 2002 | 2 | 0.060 |
Why?
|
Asbestosis | 1 | 2002 | 5 | 0.050 |
Why?
|
Asbestos, Crocidolite | 1 | 2002 | 2 | 0.050 |
Why?
|
Mining | 1 | 2002 | 3 | 0.050 |
Why?
|
Chlamydophila Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
Transportation | 1 | 2002 | 18 | 0.050 |
Why?
|
Blood Glucose | 1 | 2006 | 873 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2002 | 27 | 0.050 |
Why?
|
Olfaction Disorders | 1 | 2003 | 62 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2007 | 1015 | 0.050 |
Why?
|
Lamin Type A | 1 | 2022 | 24 | 0.050 |
Why?
|
Germ Cells | 1 | 2022 | 126 | 0.050 |
Why?
|
HLA-B27 Antigen | 1 | 2001 | 8 | 0.050 |
Why?
|
Protein Array Analysis | 1 | 2021 | 50 | 0.050 |
Why?
|
Calcium Chloride | 1 | 2001 | 9 | 0.050 |
Why?
|
Aging | 1 | 2006 | 689 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2001 | 18 | 0.050 |
Why?
|
Spinal Cord Compression | 1 | 2021 | 27 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2021 | 50 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2005 | 912 | 0.050 |
Why?
|
Computational Biology | 2 | 2015 | 528 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2007 | 826 | 0.050 |
Why?
|
Transcriptional Activation | 1 | 2002 | 280 | 0.050 |
Why?
|
Chemoprevention | 1 | 2021 | 91 | 0.050 |
Why?
|
Disease Susceptibility | 1 | 2021 | 192 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2014 | 1203 | 0.050 |
Why?
|
Frail Elderly | 1 | 2021 | 71 | 0.050 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2000 | 54 | 0.050 |
Why?
|
Propylene Glycols | 1 | 2000 | 30 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 376 | 0.050 |
Why?
|
Nasopharynx | 1 | 2000 | 47 | 0.050 |
Why?
|
Family | 2 | 2016 | 311 | 0.050 |
Why?
|
Yersinia Infections | 1 | 2000 | 5 | 0.050 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2000 | 47 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2002 | 2227 | 0.050 |
Why?
|
Transcriptional Elongation Factors | 1 | 2020 | 23 | 0.050 |
Why?
|
Antibodies, Viral | 1 | 2021 | 293 | 0.050 |
Why?
|
Karyotyping | 1 | 2020 | 250 | 0.050 |
Why?
|
Yersinia enterocolitica | 1 | 2000 | 18 | 0.050 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2001 | 314 | 0.050 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2001 | 112 | 0.050 |
Why?
|
Iliac Artery | 1 | 2000 | 35 | 0.050 |
Why?
|
Mice, Inbred C57BL | 3 | 2001 | 3087 | 0.050 |
Why?
|
Infant | 3 | 2012 | 3036 | 0.050 |
Why?
|
Geriatric Assessment | 1 | 2021 | 166 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2000 | 88 | 0.050 |
Why?
|
Azithromycin | 1 | 1999 | 13 | 0.050 |
Why?
|
Aorta, Abdominal | 1 | 2000 | 60 | 0.050 |
Why?
|
Chromosome Deletion | 1 | 2000 | 228 | 0.050 |
Why?
|
Arthritis, Infectious | 1 | 1999 | 16 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2002 | 435 | 0.050 |
Why?
|
Fractures, Bone | 1 | 2021 | 131 | 0.050 |
Why?
|
Antigens, Bacterial | 1 | 2000 | 134 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2021 | 456 | 0.040 |
Why?
|
Mastectomy | 1 | 2021 | 234 | 0.040 |
Why?
|
Women's Health | 2 | 2008 | 100 | 0.040 |
Why?
|
Haplotypes | 2 | 2014 | 642 | 0.040 |
Why?
|
Liquid Biopsy | 1 | 2019 | 33 | 0.040 |
Why?
|
Precancerous Conditions | 1 | 2000 | 196 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 1671 | 0.040 |
Why?
|
Glioma | 1 | 2001 | 285 | 0.040 |
Why?
|
Epigenomics | 1 | 2019 | 98 | 0.040 |
Why?
|
Antigens, CD | 1 | 2000 | 457 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 877 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2019 | 195 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 476 | 0.040 |
Why?
|
Diabetic Angiopathies | 1 | 1997 | 62 | 0.040 |
Why?
|
International Cooperation | 2 | 2008 | 126 | 0.040 |
Why?
|
Hypertriglyceridemia | 1 | 1997 | 67 | 0.040 |
Why?
|
ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
Polycomb Repressive Complex 1 | 1 | 2016 | 4 | 0.040 |
Why?
|
Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 8 | 0.040 |
Why?
|
Algorithms | 2 | 2016 | 1828 | 0.040 |
Why?
|
Hypercholesterolemia | 1 | 1997 | 161 | 0.040 |
Why?
|
Asia | 1 | 2016 | 94 | 0.040 |
Why?
|
Milk | 1 | 1996 | 53 | 0.040 |
Why?
|
Rabbits | 3 | 2002 | 636 | 0.040 |
Why?
|
Antibodies, Bacterial | 3 | 2006 | 95 | 0.030 |
Why?
|
Barbering | 1 | 2015 | 1 | 0.030 |
Why?
|
Textile Industry | 1 | 2015 | 2 | 0.030 |
Why?
|
Body Weight | 2 | 2008 | 459 | 0.030 |
Why?
|
Time Factors | 3 | 2013 | 5198 | 0.030 |
Why?
|
Aorta | 3 | 2002 | 280 | 0.030 |
Why?
|
Cooking | 1 | 1996 | 53 | 0.030 |
Why?
|
Rats | 3 | 2012 | 3984 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 977 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2001 | 763 | 0.030 |
Why?
|
Biomarkers | 2 | 2013 | 1709 | 0.030 |
Why?
|
Risk Assessment | 2 | 2016 | 2253 | 0.030 |
Why?
|
Butyrophilins | 1 | 2015 | 22 | 0.030 |
Why?
|
Heart Transplantation | 1 | 2000 | 705 | 0.030 |
Why?
|
Linear Models | 2 | 2007 | 419 | 0.030 |
Why?
|
Precision Medicine | 1 | 2019 | 394 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2010 | 1752 | 0.030 |
Why?
|
Survival Rate | 2 | 2013 | 1856 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 1995 | 286 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2014 | 251 | 0.030 |
Why?
|
Diabetes Mellitus | 2 | 2012 | 801 | 0.030 |
Why?
|
Transplantation, Homologous | 2 | 2010 | 996 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2011 | 2369 | 0.030 |
Why?
|
Social Class | 1 | 2014 | 127 | 0.030 |
Why?
|
Maintenance Chemotherapy | 1 | 2013 | 76 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2016 | 403 | 0.030 |
Why?
|
Apoptosis | 1 | 2000 | 1678 | 0.030 |
Why?
|
Salmonella Food Poisoning | 1 | 1992 | 4 | 0.030 |
Why?
|
Arthritis, Reactive | 1 | 1992 | 2 | 0.030 |
Why?
|
Infectious Mononucleosis | 1 | 2012 | 6 | 0.030 |
Why?
|
Registries | 2 | 2011 | 702 | 0.030 |
Why?
|
Reproductive Physiological Phenomena | 1 | 2012 | 4 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 153 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2006 | 1040 | 0.030 |
Why?
|
National Health Programs | 1 | 2012 | 20 | 0.030 |
Why?
|
Cost of Illness | 1 | 2013 | 150 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2012 | 60 | 0.030 |
Why?
|
Flank Pain | 1 | 2012 | 5 | 0.030 |
Why?
|
Xanthophylls | 1 | 2011 | 2 | 0.030 |
Why?
|
Cryptoxanthins | 1 | 2011 | 2 | 0.030 |
Why?
|
Ceftriaxone | 1 | 2012 | 9 | 0.030 |
Why?
|
Edible Grain | 1 | 2011 | 9 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
Abdominal Abscess | 1 | 2012 | 22 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2012 | 69 | 0.030 |
Why?
|
Headache | 1 | 2012 | 73 | 0.030 |
Why?
|
Carcinoma, Papillary | 1 | 2013 | 158 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2014 | 1074 | 0.030 |
Why?
|
Gastroenteritis | 1 | 2011 | 27 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2011 | 114 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2006 | 1562 | 0.020 |
Why?
|
Health Care Costs | 1 | 2013 | 237 | 0.020 |
Why?
|
Alleles | 1 | 2014 | 1127 | 0.020 |
Why?
|
Drainage | 1 | 2012 | 157 | 0.020 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2010 | 22 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2010 | 1975 | 0.020 |
Why?
|
Mutation | 1 | 2022 | 3952 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2012 | 137 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2014 | 576 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 2011 | 104 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2010 | 135 | 0.020 |
Why?
|
Sheep | 1 | 2010 | 238 | 0.020 |
Why?
|
Prevalence | 1 | 2014 | 1239 | 0.020 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2010 | 14 | 0.020 |
Why?
|
Community Health Services | 1 | 2011 | 80 | 0.020 |
Why?
|
Blood Sedimentation | 1 | 2010 | 13 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2010 | 127 | 0.020 |
Why?
|
Cryopreservation | 1 | 2010 | 68 | 0.020 |
Why?
|
Siblings | 1 | 2010 | 111 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2011 | 109 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2009 | 87 | 0.020 |
Why?
|
Isoantibodies | 1 | 2010 | 114 | 0.020 |
Why?
|
Aorta, Thoracic | 1 | 2010 | 165 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
Calcinosis | 1 | 2010 | 224 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2011 | 326 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 1168 | 0.020 |
Why?
|
Anemia, Hemolytic | 1 | 2008 | 19 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 1987 | 0.020 |
Why?
|
Connecticut | 1 | 2007 | 27 | 0.020 |
Why?
|
Body Height | 1 | 2008 | 99 | 0.020 |
Why?
|
Demography | 1 | 2008 | 177 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2007 | 127 | 0.020 |
Why?
|
Control Groups | 1 | 2006 | 15 | 0.020 |
Why?
|
Ultraviolet Rays | 1 | 2008 | 193 | 0.020 |
Why?
|
Cell Lineage | 1 | 2008 | 273 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 1200 | 0.020 |
Why?
|
Coxiella burnetii | 1 | 2006 | 11 | 0.020 |
Why?
|
Societies, Medical | 1 | 2010 | 572 | 0.020 |
Why?
|
Biological Availability | 1 | 2006 | 92 | 0.020 |
Why?
|
Lymphatic System | 1 | 2006 | 52 | 0.020 |
Why?
|
Blood Vessels | 1 | 2006 | 94 | 0.020 |
Why?
|
Illinois | 1 | 2007 | 461 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2008 | 206 | 0.020 |
Why?
|
Genetic Variation | 1 | 2012 | 1349 | 0.020 |
Why?
|
Gene Frequency | 1 | 2007 | 676 | 0.020 |
Why?
|
Breast | 1 | 2007 | 286 | 0.020 |
Why?
|
Ovarian Neoplasms | 2 | 1999 | 738 | 0.020 |
Why?
|
Epithelium | 2 | 2000 | 317 | 0.020 |
Why?
|
Electrophoresis, Cellulose Acetate | 1 | 1984 | 3 | 0.020 |
Why?
|
Dermatan Sulfate | 1 | 1984 | 9 | 0.020 |
Why?
|
Proteins | 1 | 1990 | 777 | 0.020 |
Why?
|
Celiac Disease | 1 | 2008 | 202 | 0.020 |
Why?
|
Psoriasis | 1 | 2008 | 239 | 0.020 |
Why?
|
Glycosaminoglycans | 1 | 1984 | 47 | 0.020 |
Why?
|
Chondroitin Sulfates | 1 | 1984 | 43 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2006 | 551 | 0.020 |
Why?
|
Transfection | 1 | 2006 | 895 | 0.020 |
Why?
|
Magnesium | 1 | 2005 | 177 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2010 | 1796 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2010 | 1381 | 0.020 |
Why?
|
Electrocardiography | 1 | 2006 | 478 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2007 | 502 | 0.010 |
Why?
|
Sarcoma | 1 | 1984 | 211 | 0.010 |
Why?
|
Azo Compounds | 1 | 2002 | 13 | 0.010 |
Why?
|
Cholesterol, Dietary | 1 | 2002 | 27 | 0.010 |
Why?
|
Biotransformation | 1 | 2002 | 50 | 0.010 |
Why?
|
Coloring Agents | 1 | 2002 | 64 | 0.010 |
Why?
|
Tunica Intima | 1 | 2002 | 59 | 0.010 |
Why?
|
Radioimmunotherapy | 1 | 2002 | 25 | 0.010 |
Why?
|
Vaccines, DNA | 1 | 2001 | 16 | 0.010 |
Why?
|
Molecular Mimicry | 1 | 2001 | 20 | 0.010 |
Why?
|
Histocompatibility Antigens | 1 | 2001 | 35 | 0.010 |
Why?
|
HLA-A2 Antigen | 1 | 2001 | 31 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 2001 | 186 | 0.010 |
Why?
|
Dilatation, Pathologic | 1 | 2001 | 54 | 0.010 |
Why?
|
Tobacco, Smokeless | 1 | 2001 | 10 | 0.010 |
Why?
|
Rheumatic Diseases | 1 | 2001 | 20 | 0.010 |
Why?
|
Plants, Toxic | 1 | 2001 | 26 | 0.010 |
Why?
|
Sodium Chloride | 1 | 2001 | 86 | 0.010 |
Why?
|
Immunization | 1 | 2001 | 158 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2001 | 213 | 0.010 |
Why?
|
Animals, Genetically Modified | 1 | 2001 | 181 | 0.010 |
Why?
|
Echocardiography | 1 | 2006 | 911 | 0.010 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2002 | 231 | 0.010 |
Why?
|
Rats, Inbred BN | 1 | 2000 | 37 | 0.010 |
Why?
|
Rats, Inbred WKY | 1 | 2000 | 31 | 0.010 |
Why?
|
Fingolimod Hydrochloride | 1 | 2000 | 29 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 2000 | 85 | 0.010 |
Why?
|
Sphingosine | 1 | 2000 | 71 | 0.010 |
Why?
|
Phagocytes | 1 | 2000 | 10 | 0.010 |
Why?
|
Spleen | 1 | 2001 | 430 | 0.010 |
Why?
|
Antigen Presentation | 1 | 2001 | 209 | 0.010 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2000 | 43 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 2000 | 66 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 1148 | 0.010 |
Why?
|
Prosthesis Failure | 1 | 2000 | 111 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2000 | 149 | 0.010 |
Why?
|
Rectum | 1 | 2000 | 146 | 0.010 |
Why?
|
Databases as Topic | 1 | 1999 | 92 | 0.010 |
Why?
|
Device Removal | 1 | 2000 | 159 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2001 | 727 | 0.010 |
Why?
|
Fibroblasts | 1 | 2001 | 729 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2000 | 277 | 0.010 |
Why?
|
Vena Cava, Inferior | 1 | 2000 | 143 | 0.010 |
Why?
|
Acute Disease | 1 | 2000 | 824 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2000 | 444 | 0.010 |
Why?
|
Rural Population | 1 | 1998 | 136 | 0.010 |
Why?
|
Disabled Persons | 1 | 1998 | 67 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2001 | 2810 | 0.010 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 1995 | 21 | 0.010 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1995 | 47 | 0.010 |
Why?
|
Molecular Weight | 1 | 1995 | 332 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2000 | 1918 | 0.010 |
Why?
|
Blotting, Western | 1 | 1995 | 781 | 0.010 |
Why?
|
Salmonella enteritidis | 1 | 1992 | 4 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1992 | 154 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1984 | 2260 | 0.010 |
Why?
|
Antibody Formation | 1 | 1992 | 171 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1992 | 177 | 0.010 |
Why?
|
Parathyroid Hormone-Related Protein | 1 | 1990 | 12 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1990 | 155 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2000 | 2183 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1990 | 104 | 0.010 |
Why?
|
Peritoneal Neoplasms | 1 | 1990 | 175 | 0.010 |
Why?
|
Epithelial Cells | 1 | 1990 | 662 | 0.000 |
Why?
|